Drugs / SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351)
SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351)
also known as
CoV2 preS dTM/D614+B.1.351
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04904549 | May 2021 → Aug 2024 | COVID-19 | Sanofi Pasteur, a Sanofi Company | Terminated | Met primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04904549 ↗ |
| Known as | CoV2 preS dTM/D614+B.1.351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05289037 ↗ |
| Modality | Vaccine | “bivalent SARS-CoV-2 recombinant protein vaccine” PMID 37716365 ↗ Sep 2023 |
| Route | Intramuscular | “Route of administration: intramuscular injection.” NCT04904549 ↗ |